GOSS Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Gossamer Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$1.55 |
| 52 Week Low | US$0.50 |
| Beta | 1.82 |
| 1 Month Change | 28.16% |
| 3 Month Change | -8.13% |
| 1 Year Change | 95.16% |
| 3 Year Change | -83.76% |
| 5 Year Change | -90.90% |
| Change since IPO | -93.70% |
Recent News & Updates
Phase III Trials And Global Collaborations Will Expand Treatment Horizons
Successful Phase III study enrollment and collaboration enhance market reach, promising revenue growth through potential positive efficacy results and expanded indications.Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection
May 02Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Feb 14Recent updates
Phase III Trials And Global Collaborations Will Expand Treatment Horizons
Successful Phase III study enrollment and collaboration enhance market reach, promising revenue growth through potential positive efficacy results and expanded indications.Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection
May 02Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Feb 14Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Sep 10Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts
Aug 14
Peaking Back In On Gossamer Bio
Sep 27Gossamer Bio to raise $120M in a private equity placement
Jul 13Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?
Jun 25Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?
Jan 19Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?
Sep 22Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares
Jan 28Shareholder Returns
| GOSS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.6% | 0.4% | 0.8% |
| 1Y | 95.2% | -9.6% | 11.5% |
Return vs Industry: GOSS exceeded the US Biotechs industry which returned -9.6% over the past year.
Return vs Market: GOSS exceeded the US Market which returned 11.5% over the past year.
Price Volatility
| GOSS volatility | |
|---|---|
| GOSS Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: GOSS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GOSS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 145 | Faheem Hasnain | www.gossamerbio.com |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
Gossamer Bio, Inc. Fundamentals Summary
| GOSS fundamental statistics | |
|---|---|
| Market cap | US$263.67m |
| Earnings (TTM) | -US$51.24m |
| Revenue (TTM) | US$124.59m |
Is GOSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GOSS income statement (TTM) | |
|---|---|
| Revenue | US$124.59m |
| Cost of Revenue | US$0 |
| Gross Profit | US$124.59m |
| Other Expenses | US$175.83m |
| Earnings | -US$51.24m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -41.13% |
| Debt/Equity Ratio | -3,164.2% |
How did GOSS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 00:20 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gossamer Bio, Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Gould | Barclays |
| Zhilin Long | Berenberg |
| Patrick Trucchio | Berenberg |